Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. [electronic resource]
Producer: 20190715Description: 231-237 p. digitalISSN:- 1527-7755
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Aniline Compounds -- adverse effects
- Antineoplastic Agents -- adverse effects
- Biomarkers, Tumor -- genetics
- Disease Progression
- Female
- Fusion Proteins, bcr-abl -- genetics
- Genetic Predisposition to Disease
- Humans
- Imatinib Mesylate -- adverse effects
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Male
- Middle Aged
- Nitriles -- adverse effects
- Phenotype
- Philadelphia Chromosome
- Protein Kinase Inhibitors -- adverse effects
- Quinolines -- adverse effects
- Time Factors
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.